Cardiotoxicity of antimalarial drugs;La toxicite cardiaque des antipaludeens

Medecine et Maladies Infectieuses

Volumn 29, Issue SUPPL. 3, 1999, Pages 316-325

  Touze, J E ^a   Heno, P ^a   Fourcade, L ^a   Deharo, J C ^b   Mafart, B ^a   Lemaitre, X ^c  

^a Service de Cardiologie   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antimalarial drugs; Cardiac arrhythmias; Malaria; Malaria therapy

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; BEPRIDIL; CHLOROQUINE; CICLETANINE; CLAVULANIC ACID; COTRIMOXAZOLE; DISOPYRAMIDE; ERYTHROMYCIN; HALOFANTRINE; IBUTILIDE; IBUTILIDE FUMARATE; MEFLOQUINE; PROBUCOL; PROGUANIL; QUINIDINE; QUININE; SOTALOL; SPIRAMYCIN; TAFENOQUINE; TERFENADINE; THIORIDAZINE;

BRADYCARDIA; CARDIOTOXICITY; CONFERENCE PAPER; HEART ATRIUM FLUTTER; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOKALEMIA; LONG TERM CARE; MALARIA; PRACTICE GUIDELINE; PRESCRIPTION; QT INTERVAL; RESTRICTIVE CARDIOMYOPATHY;

EID: 0033382283     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Bustos MD, Gay F, Diquet B, Thomare P, Warot D. The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects. Trop Med Parasitol 1994 ; 45 : 83-6.
2. Bertrand E, Clerc G, Renambot J, Odi-Assamoi J, Chauvet J. Cinquante cas de paludisme aigu. Étude symptomatologique et notamment cardiaque. Bull Soc Pathol Exot 1975 ; 68 : 456-66.
3. Iglesias Cubero G, Rodriguez Reguero JJ, Rojo Ortega JM. Restrictive cardiomyopathy caused by chloroquine. Br Heart J 1993 ; 69 : 451-2.
4. Veinot JP, Mai KT, Zarychansky R. Chloroquine related cardiac toxicity. J Rheumatol 1998 ; 25 : 1221-5.
5. Guedira N, Hajjaj-Hassouni N, Srairi JE, el Hassani S, Fellat R, Benomar M. Third-degree atrioventricular block in a patient under chloroquine therapy. Rev Rhum Engl 1998 ; 65 : 58-62.
6. Ratliff NB, Estes ML, Myles JL. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med 1987 ; 316 : 191-3.
7. August C, Holzhausen HJ, Schmoldt A, Pompecki R, Schroder S. Histological and ultrastructural findings in chloroquine-induced cardiomyopathy. J Mol Med 1995 ; 73 : 73-7.
8. Fellahi JL, Dumazer P, Delayance S, Vernier I, Conte JJ. Cardiomyopathie sous traitement par hydroxychloroquine révélée par un bloc auriculoventriculaire complet. Rev Méd Interne 1993 ; 14 : 275-6.
9. Sukontason K, Karbwang J, Rimchala W, Tin-T, Na-Bangchang K, Banmairuroi V, et al. Plasma quinine concentrations in falciparum malaria with acute renal failure. Trop Med Int Health 1996 ; 1 : 236-42.
10. White NJ, Looareesuwan S, Warrell DA, Chanthavanich S, Phillips RE, Pongpaew P. Quinine loading dose in cerebral malaria. Am J Trop Med Hyg 1983 ; 32 : 1-5.
11. Karbwang J, Davis TME, Looareesuwan S, Molunto P, Bunnag D, White NJ. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. Br J Clin Pharmacol 1993 ; 35 : 265-71.
12. Bonington A, Davidson RN, Winstanley PA, Pasvol G. Fatal quinine cardiotoxicity in the treatment of falciparum malaria. Trans R Soc Trop Med Hyg 1996 ; 90 : 305-7.
13. Silamut K, Molunto P, Ho M, Davis TME, White NJ. α-1 acid-glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br J Clin Pharmacol 1991 ; 32 : 311-5.
14. Davis TM, Suparanavond W, Pukrittayamee S, Kabwang J, Molunto P, Meckyhon S, et al. A safe and effective consecutive-infusion regimen for rapid quinine loading in severe malaria. J Infect Dis 1990 ; 161 : 1305-8.
15. Davis TM, Dembo LG, Kaye-Eddie SA, Hewitt BJ, Hislop RG, Batty KT. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo controlled trial. Br J Clin Pharmacol 1996 ; 42 : 415-21.
16. Bodenhamer JE, Smilkstein MJ. Delayed cardiotoxicity following quinine overdose: a case report. J Emerg Med 1993 ; 11 : 279-85.
17. Bateman D, Blain PG, Woodhouse KW, Rawlins MD, Dyson EH, Heyworth R, et al. Pharmacokinetics and clinical toxicity of quinine overdosage: lack of efficacy of techniques intended to enhance elimination. Q J Med 1985 ; 54 : 125-31.
18. Boland ME, Roper SM, Henry JA. Complications of quinine poisoning. Lancet 1985 ; i : 384-5.
19. Jacqz Aigrain E, Bennasr S, Desplanques L, Peralma A, Beaufils F. Severe poisoning risk linked to intravenous administration of quinine. Arch Pédiatr 1994 ; 1 : 14-9.
20. Martin ES, Rogalski K, Black JN. Quinine may trigger torsades de pointes during astemizole therapy. Pacing Clin Electrophysiol 1997 ; 20 : 2024-5.
21. Hachfi SF, Coudert V, Biron R, Barois A. Intoxication aiguë à la quinine traitée par diazépam à fortes doses. Arch Fr Pédiatr 1993 ; 50 : 485-8.
22. Jurkiewicz MK, Rodzinski JA, Colarski TA. Antiarrhythmic action of quinidine: relative importance of QT prolongation versus use dependence. Circulation 1985 ; 71 Suppl II : II-225 [abstract].
23. Klevans LR, Kelly RJ, Kovaco JL. Comparison of the antiarrhythmic activity of quinidine and quinine. Arch Int Pharmacodyn 1978 ; 227 : 57-68.
24. Sheldon R, Duff H, Koshman ML. Antiarrhythmic activity of quinine in humans. Circulation 1995 ; 92 : 2944-50.
25. Bryson M, Goa KL. Halofantrine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992 ; 43 : 236-58.
26. Vincent MP, Becquart JP, Receveur MC, Nordor O, Lebras M. Surdosage à l'halofantrine. Presse Méd 1992 ; 21 : 131.
27. Ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaipun L, et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 1993 ; 341 : 1044-9.
28. Nosten F, Ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993 ; 341 : 1054-6.
29. Castot A, Rapoport P, Le Coz P. Prolonged QT interval with halofantrine. Lancet 1993 ; 341 : 1541-2.
30. Monlun E, Pillet, Cochard JF, Lebras M. Prolonged QT interval with halofantrine. Lancet 1993 ; 341 : 1541-2.
31. Toivonen L, Viitasalo M, Siiikamaki H, Raatikka M, Pohjola-Sintonen S. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome. Clin Cardiol 1994 ; 17 : 403-4.
32. Akkhtar T, Imran M. Sudden death while on halofantrine treatments. A report of two cases from Peshawar. J Pak Med Assoc 1994; 44: 120-1.
33. Gundersen SG, Rostrup M, von der Lippe E, Platou ES, Myrvang B, Edwards G. Halofantrine associated ventricular fibrillation in a young woman with no predisposing QTc prolongation. Scand J Infect Dis 1997 ; 29 : 207-8.
34. Touze JE, Deharo JC, Imbert P, Fourcade L. Effets proarythmiques de l'halofantrine. Presse Méd 1994 ; 23 : 1450-1.
35. Evans SJW, Waller P. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1997 ; 43 : 665.
36. Jaspers CAJJ, Hopperus Buma APCC, Van Thiel PPAM, Van Hulst RA, Kager PA. Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996 ; 55 : 230-4.
37. Supanaranond W, Suputtamongkol Y, Davis TM, Pukrittayakamee S, Teja-Isavadharm P, Webster HK, et al. Lack of significant adverse cardiovascular effect of combined quinine and mefloquine therapy for uncomplicated malaria. Trans R Soc Trop Med Hyg 1997 ; 91 : 694-6.
38. Loathavorn P, Karbwang J, Na Bangchang K, Bunnag D, Harinasuta T. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients. South Asian J Trop Med Public Health 1992 ; 23 : 51-4.
39. Fonteyne W, Bauwens A, Jordaens L. Atrial flutter with 1:1 conduction after administration of the antimalarial drug mefloquine. Clin Cardiol 1996 ; 19 : 967-8.
40. Richter J, Burbach G, Hellgren U, Dengler A, Bienzle U Aberrant atrioventricular conduction trigerred by antimalarial prophylaxis with mefloquine. Lancet 1997 ; 349 : 101-2.
41. Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P, et al. Mefloquine compared with other malaria chemoprophylactic regimen in tourists visiting East Africa. Lancet 1993 ; 341 : 848-51.
42. Meshnik SR, Tsang TW, Lin FB, Pan HZ, Chang CN, Kuypers D, et al. Activated oxygen mediates the antimalarial activity of qinghaosu. Prog Clin Biol Res 1989 ; 313 : 95-104.
43. Meshnik SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antiamalarial endoperoxydes: from herbal remedy to targeted chemotherapy. Microbiol Rev 1996b ; 60 : 301-15.
44. Ribeyro I, Olliaro P. Are QHS derivatives tolerated in patients? What are the most common adverse effects? Are there any clinical correlates to neurotox findings in animal? The rational use of qinghaosu and its derivatives [proceedings]; 19-22 avril 1998; Les Pensieres, Annecy; Rhône-Poulenc-Rorer. p. 51-9.
45. Karbwang J, Laothavorn P, Sukontason K, Thiha T, Rimchala W, Na-Bangchang K, et al. Effect of artemether on electrocardiogram in severe falciparum malaria. South Asian J Trop Med Public Health 1997 ; 28 : 472-5.
46. Jaeger A, Raguin O, Liegeon MN. Intoxications aiguës par les antiarythmiques de la classe I et par la chloroquine. Rev Prat 1997 ; 47 : 748-53.
47. Karbwang J, Na Bangchang K. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 1994 ; 27 : 104-19.
48. Touze JE, Bernard J, Keundjian A, Imbert P, Chaudet H, Doury JC. Electrocardiographic changes and halofantrine plasma levels during acute falciparum malaria. Am J Trop Med Hyg 1996 ; 54 : 225-8.
49. Tobe TJ, De Langen DJ, Bink-Boelkens MT, Mook PH, Viersma JW, Lie KI, et al. Late potentials in a bradycardia-dependent long QT syndrome associated with sudden death during sleep. J Am Coll Cardiol 1992 ; 19 : 541-9.
50. Roden DM, Thompson KA, Hoffman BF, Woosley R. Clinical features and basic mechanisms of quinidine-induced arrythmias. J Am Coll Cardiol 1986 ; 8 : A73-8.
51. Freedman RA, Steinberg JS. Selective prolongation of QRS late potentials by sodium channel blocking antiarrhythmic drugs: relation to slowing of ventricular tachycardia. J Am Coll Cardiol 1991 ; 17 : 1017-25.
52. World Healh Organisation. Severe and complicated falciparum malaria. Trans R Soc Trop Med Hyg 1990 ; 84 Suppl 2 : 1-65.
53. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovascular Pharmacol 1983 ; 5 : 173-5.
54. Annales du contrôle de qualité national en parasitologie. Mars 1993, février 1994, janvier 1996.
55. Touze JE, Peyron F, Mojon M, Fourcade L. Halofantrine : pour de nouvelles règles de prescription. Presse Méd 1995 ; 24 : 366-9.
56. Touze JE, Peyron F, Fourcade L, Héno P, Deharo JC. Is halofantrine still advisable in malaria attacks? Ann Trop Med Parasitol 1997 ; 91 : 867-73.
57. Wirima J, Khoromana C, Molyneux ME, Gilles HM. Clinical trials with halofantrine hydrochloride in Malawi. Lancet 1988 ; ii : 250-2.
58. Touze JE, Perret JL, Nicolas X, Bernard J, Fourcade L, Keundjian A, et al. Efficacy of low-dose halofantrine for second treatment of uncomplicated falciparum malaria. Lancet 1997 ; 349 : 255-6.
59. White NJ. The treatment of malaria. N Engl J Med 1996 ; 335 : 800-6.